Cargando…

Renal Injury during Long-Term Crizotinib Therapy

Crizotinib is highly effective against anaplastic lymphoma kinase-positive and c-ros oncogen1-positive non-small cell lung cancer. Renal dysfunction is associated with crizotinib therapy but the mechanism is unknown. Here, we report a case of anaplastic lymphoma kinase positive non-small cell lung c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasuma, Taro, Kobayashi, Tetsu, D’Alessandro-Gabazza, Corina N., Fujimoto, Hajime, Ito, Kentaro, Nishii, Yoichi, Nishihama, Kota, Baffour Tonto, Prince, Takeshita, Atsuro, Toda, Masaaki, Gabazza, Esteban C., Taguchi, Osamu, Yonemura, Shigenori, Hataji, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213486/
https://www.ncbi.nlm.nih.gov/pubmed/30257437
http://dx.doi.org/10.3390/ijms19102902
_version_ 1783367782310608896
author Yasuma, Taro
Kobayashi, Tetsu
D’Alessandro-Gabazza, Corina N.
Fujimoto, Hajime
Ito, Kentaro
Nishii, Yoichi
Nishihama, Kota
Baffour Tonto, Prince
Takeshita, Atsuro
Toda, Masaaki
Gabazza, Esteban C.
Taguchi, Osamu
Yonemura, Shigenori
Hataji, Osamu
author_facet Yasuma, Taro
Kobayashi, Tetsu
D’Alessandro-Gabazza, Corina N.
Fujimoto, Hajime
Ito, Kentaro
Nishii, Yoichi
Nishihama, Kota
Baffour Tonto, Prince
Takeshita, Atsuro
Toda, Masaaki
Gabazza, Esteban C.
Taguchi, Osamu
Yonemura, Shigenori
Hataji, Osamu
author_sort Yasuma, Taro
collection PubMed
description Crizotinib is highly effective against anaplastic lymphoma kinase-positive and c-ros oncogen1-positive non-small cell lung cancer. Renal dysfunction is associated with crizotinib therapy but the mechanism is unknown. Here, we report a case of anaplastic lymphoma kinase positive non-small cell lung cancer showing multiple cysts and dysfunction of the kidneys during crizotinib administration. We also present results demonstrating that long-term crizotinib treatment induces fibrosis and dysfunction of the kidneys by activating the tumor necrosis factor-α/nuclear factor-κB signaling pathway. In conclusion, this study shows the renal detrimental effects of crizotinib, suggesting the need of careful monitoring of renal function during crizotinib therapy.
format Online
Article
Text
id pubmed-6213486
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62134862018-11-14 Renal Injury during Long-Term Crizotinib Therapy Yasuma, Taro Kobayashi, Tetsu D’Alessandro-Gabazza, Corina N. Fujimoto, Hajime Ito, Kentaro Nishii, Yoichi Nishihama, Kota Baffour Tonto, Prince Takeshita, Atsuro Toda, Masaaki Gabazza, Esteban C. Taguchi, Osamu Yonemura, Shigenori Hataji, Osamu Int J Mol Sci Communication Crizotinib is highly effective against anaplastic lymphoma kinase-positive and c-ros oncogen1-positive non-small cell lung cancer. Renal dysfunction is associated with crizotinib therapy but the mechanism is unknown. Here, we report a case of anaplastic lymphoma kinase positive non-small cell lung cancer showing multiple cysts and dysfunction of the kidneys during crizotinib administration. We also present results demonstrating that long-term crizotinib treatment induces fibrosis and dysfunction of the kidneys by activating the tumor necrosis factor-α/nuclear factor-κB signaling pathway. In conclusion, this study shows the renal detrimental effects of crizotinib, suggesting the need of careful monitoring of renal function during crizotinib therapy. MDPI 2018-09-25 /pmc/articles/PMC6213486/ /pubmed/30257437 http://dx.doi.org/10.3390/ijms19102902 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Yasuma, Taro
Kobayashi, Tetsu
D’Alessandro-Gabazza, Corina N.
Fujimoto, Hajime
Ito, Kentaro
Nishii, Yoichi
Nishihama, Kota
Baffour Tonto, Prince
Takeshita, Atsuro
Toda, Masaaki
Gabazza, Esteban C.
Taguchi, Osamu
Yonemura, Shigenori
Hataji, Osamu
Renal Injury during Long-Term Crizotinib Therapy
title Renal Injury during Long-Term Crizotinib Therapy
title_full Renal Injury during Long-Term Crizotinib Therapy
title_fullStr Renal Injury during Long-Term Crizotinib Therapy
title_full_unstemmed Renal Injury during Long-Term Crizotinib Therapy
title_short Renal Injury during Long-Term Crizotinib Therapy
title_sort renal injury during long-term crizotinib therapy
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213486/
https://www.ncbi.nlm.nih.gov/pubmed/30257437
http://dx.doi.org/10.3390/ijms19102902
work_keys_str_mv AT yasumataro renalinjuryduringlongtermcrizotinibtherapy
AT kobayashitetsu renalinjuryduringlongtermcrizotinibtherapy
AT dalessandrogabazzacorinan renalinjuryduringlongtermcrizotinibtherapy
AT fujimotohajime renalinjuryduringlongtermcrizotinibtherapy
AT itokentaro renalinjuryduringlongtermcrizotinibtherapy
AT nishiiyoichi renalinjuryduringlongtermcrizotinibtherapy
AT nishihamakota renalinjuryduringlongtermcrizotinibtherapy
AT baffourtontoprince renalinjuryduringlongtermcrizotinibtherapy
AT takeshitaatsuro renalinjuryduringlongtermcrizotinibtherapy
AT todamasaaki renalinjuryduringlongtermcrizotinibtherapy
AT gabazzaestebanc renalinjuryduringlongtermcrizotinibtherapy
AT taguchiosamu renalinjuryduringlongtermcrizotinibtherapy
AT yonemurashigenori renalinjuryduringlongtermcrizotinibtherapy
AT hatajiosamu renalinjuryduringlongtermcrizotinibtherapy